'ILC Therapeutics' CEO Owain Millington has authored an article in the winter issue of Drug Discovery World, on some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development.
Newsroom
Keeping you updated
Manufacturing Chemist article: Hybrid interferons: developing a novel drug class
Dawn Firmin, ILC Therapeutics Chief Operating Officer, spoke with Manufacturing Chemist about how the Company is pioneering a novel drug class called hybrid interferons.
COVID: Antiviral drugs that boost humans’ ‘interferon’ immune response can help tackle current and future pandemics – Professor William Stimson
As we live through the most rapidly evolving viral environment the world has seen, there is a critical need for effective and safe antiviral medicines to meet the challenges of today and the inevitable threats of tomorrow. Worldwide, we are
Inventor of synthetic Interferon discusses potential against COVID-19
An interview with Founder & Chief Scientific Officer William Stimson in Drug Discovery World.